For more than a decade, pulmonologist Dr. Dan Sterman has believed immunotherapy would become the catalyst for major advancements in the treatment of malignant pleural mesothelioma.
Today, he is closer than ever to proving that point.
Sterman, director of pulmonary medicine at New York University, soon will help launch a multicenter clinical trial involving a powerful immunogene therapy combination that may change the way this deadly asbestos-related cancer is viewed.
“I believe that immunotherapy will become the fourth pillar of treatment for mesothelioma (joining chemotherapy, radiation and surgery),” Sterman told Asbestos.com. “It won’t be one immunotherapy drug, but a cocktail of drugs that together will help turn mesothelioma into a chronic disease that people can live with for a long time.”
Pleural mesothelioma typically comes with a prognosis of a six- to 15-month life expectancy, even with a multidisciplinary approach. Immunotherapy involves sparking a patient’s own immune system to fight the cancer.
Sterman is not predicting a cure, but an ability to provide long-term control where patients can extend their lives and maintain a good quality of life for many years.
A recent, smaller study of 40 patients with unresectable pleural mesothelioma performed in medical centers at New York University, University of Pennsylvania, and University of Maryland initiated the upcoming trial. All three centers have mesothelioma-sp…
CONCLUSIONS Our study indicates that IL-6 induces strong immunosuppression in the CRC microenvironment by recruiting immunosuppression cells and impairing T cell infiltration. Inhibition of IL-6 enhanced the efficacy of anti-PD-L1 in CRC, providing a novel strategy to overcome anti-PD-L1 resistance in CRC.
PMID: 30087314 [PubMed – in process]
CONCLUSIONS We found that hsa_circ_0004458 promoted the progression of PTC by inhibition of miR-885-5p and activation of RAC1, and hsa_circ_0004458 may serve as a potential therapeutic target and biomarker for PTC.
PMID: 30086127 [PubMed – in process]
CONCLUSIONS Girinimbine, a carbazole alkaloid used in Chinese herbal medicine, inhibited the proliferation and cell migration of human ovarian cancer cells in vitro, in a dose-dependent manner, via the PI3K/Akt/mTOR and Wnt/β-catenin signaling pathways.
PMID: 30084434 [PubMed – in process]
Purpose of review
We aim to summarize the utility of strain in monitoring the effects of cancer therapy-related cardiotoxicity (CTRC) on the development of left ventricular (LV) dysfunction.
Serial assessment of cardiac function at baseline and during treatment is recommended in patients undergoing cancer treatment. Historically, the use of left ventricular ejection fraction (LVEF) has been used to monitor for cardiac toxicity from cancer therapies but myocardial mechanic parameters, in particular global longitudinal strain (GLS), have emerged as powerful adjunctive tools. On the basis of longitudinal …
Authors: Lin X, Ozbey U, Sabitaliyevich UY, Attar R, Ozcelik B, Zhang Y, Guo M, Liu M, Alhewairini SS, Farooqi AA
Maslinic acid (2α,3β-dihydroxyolean-12-en-28-oic acid) is a naturally occurring pentacyclic triterpenic compound. Maslinic acid is gradually gaining attention as an excellent pharmacologically active product because of its premium biological properties. In this review we will focus on chemopreventive properties of Maslinic acid against different cancers. Seemingly, available data is limited and we have yet to unravel how Maslinic acid therapeutically targeted oncogenic cell signal tr…
Authors: Hongtao L, Xiaoqi G, Junni L, Feng X, Guodong B, Liang Y
Chlorogenic acid (CGA), an ester with various pharmacological effects, is important in cancer therapy. However, the specific antitumor mechanism of CGA is not entirely clear, especially with respect to its suppression of non-small cell lung cancer (NSCLC). The present study was carried out to assess the effect of CGA on NSCLC, and the mechanism involved. Cell viability assay and colony formation assay revealed that CGA blocked the proliferative capacity of NSCLC cells in vitro. Results from the migration assay suggested that CGA also inhibit…
In this study, we revisited the possibility of artesunate (ART) and chloroquine (CQ), the antimalarial drugs, as therapeutic agents against CCA. The possible mechanisms of these drugs to exert cytotoxicity on CCA cells were also explored. The effects of ART and CQ on proliferation and death patterns of two CCA cell lines, KKU-214 and its highly metastatic subtype KKU-214L5, were examined using water soluble tetrazolium (WST) assay and time-lapse photometry, respectively. To differentiate and verify the death patterns between necrosis and apoptosis, lactate dehydrogenase (LDH) release, and caspase 3 activity were measured. …
This study provides a dendritic cell-based vaccine strategy which might reduce the risk of tumor recurrence and improve the efficiency of anti-chemoresistance of bladder cancer.
PMID: 30084800 [PubMed – in process]
This study was performed to evaluate the cytotoxic effects of asiatic acid on two human CCA cell lines (KKU-156 and KKU-213). Cell viability was determined by a sulforhodamine B (SRB) assay. Morphological changes of the cells were observed by microscopy. Cell apoptosis was detected by flow cytometry using annexin V and propidium iodide (PI) staining. Messenger RNA (mRNA) expression levels of BAX, BCL2 and Survivin/BIRC5 were analyzed by real-time polymerase chain reaction (PCR). It was found that asiatic acid efficiently suppressed CCA cellular viability via induction of apoptosis. In addition, the occurrence of asiatic ac…
Conclusions: Research in this area emphasized hotspots such as squamous cell carcinoma, OC, oral submucosal fibrosis, betel quid, and tobacco. The annual number of publications steadily decreased from 1998 to 2017, with a lack of a systematic study from interdisciplinary perspectives, inadequate pertinent journals, limited regions with the practice of betel quid chewing, and insufficient participation of researchers, which indicate that as the prevalence of OC increases, particularly in China, research in this area warrants further expansion.
PMID: 30082530 [PubMed – in process]